Acetazolamide in Persons With Type 1 Diabetes - Crossover Trial
Part of paid clinical trials in La Jolla, California.
- Sponsor
- University of California, San Diego
- Study ID
- NCT06981234
- Phase
- PHASE2
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Acetazolamide — DRUGAcetazolamide is a potent carbonic anhydrase inhibitor that acts on the renal proximal tubule. Through this mechanism, it inhibits proximal tubule sodium reabsorption.
- Placebo — DRUGStandard pharmaceutical filler will be capsulated and packaged identically to the acetazolamide.
Study Details
The goal of this study is to learn about the effect of the study drug acetazolamide in individuals with Type 1 Diabetes. Specifically, whether acetazolamide provides benefits to the kidneys while minimizing any side effects of the drug. These changes will be measured by laboratory tests that tell us how well the kidneys are functioning.
Key Dates
- Start date
- Aug 14, 2024
- Status verified
- Jun 2025
- Primary completion
- Dec 31, 2026
- Completion
- Jun 30, 2027
Study Design
- Enrollment
- 25 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- CROSSOVER
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment Group A250mg Acetazolamide administered twice a day for 10 weeks followed by Placebo Comparator administered twice a day for 10 weeks.
- Experimental: Treatment Group BPlacebo Comparator administered twice a day for 10 weeks followed by 250mg Acetazolamide administered twice a day for 10 weeks.
Primary Outcome Measure
Change in mGFR percent [ Time Frame: 10 weeks ]
Central Contacts
- Todd May, MS858-246-2146
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| UC San Diego Altman Clinical & Translational Research Institute | La Jolla | California | 92037 | Todd May, MS Charles Ginsberg, MD (PRINCIPAL_INVESTIGATOR) Joe Ix, MD (SUB_INVESTIGATOR) Jeremy Pettus, MD (SUB_INVESTIGATOR) |
Find similar trials in La Jolla, CA
By condition
By specialty
Related Studies
- Effectiveness and Safety of the RIGHTEST Continuous Glucose Monitoring System for Blood Glucose Management in Persons With Diabetes MellitusNot Yet Recruiting · Bionime Corporation · Guntersville, Alabama
- ACT1VATE: Addressing Emotional Distress to Improve Outcomes Among Diverse Adults With Type 1 DiabetesPHASE2 · Recruiting · Scripps Whittier Diabetes Institute · San Diego, California
- BEAD-T1D: Building the Evidence to Address Disengagement in Type 1 DiabetesRecruiting · Stanford University · Stanford, California
- Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 DiabetesPHASE1/PHASE2 · Recruiting · University of California, San Diego · La Jolla, California